文献速递胸部介入CT

CT引导经皮微波消融治疗合并特发性肺纤维化的I期非小细胞肺癌的安全性与疗效

Safety and efficacy of CT-guided percutaneous microwave ablation for stage I non-small cell lung cancer in patients with comorbid idiopathic pulmonary fibrosis.
PubMed 文献 · Eur Radiol · 2023-12-20

回顾性单中心队列研究纳入107例临床I期非小细胞肺癌行CT引导微波消融患者,其中27例合并特发性肺纤维化、80例不合并;两组不良事件发生率相似(48.6% vs 47.7%,p=0.998),无操作相关特发性肺纤维化急性加重或死亡;特发性肺纤维化组1年/3年总生存率85.2%/51.6%低于非特发性肺纤维化组的97.5%/86.4%(p<0.001),无进展生存期无显著差异(p=0.271)。作者结论认为微波消融在合并特发性肺纤维化的I期非小细胞肺癌患者中可行,特发性肺纤维化对生存有不良影响。

要点

  • 合并特发性肺纤维化的I期非小细胞肺癌行CT引导微波消融未发生操作相关特发性肺纤维化急性加重或死亡。
  • 两组不良事件发生率相似(48.6% vs 47.7%,p=0.998),3级不良事件特发性肺纤维化组13.5% vs 非特发性肺纤维化组4.6%(p=0.123,无显著差异)。
  • 特发性肺纤维化组1年/3年总生存率85.2%/51.6%低于非特发性肺纤维化组97.5%/86.4%(p<0.001),无进展生存期无显著差异(p=0.271)。

核心结论

  • 微波消融在合并特发性肺纤维化的I期非小细胞肺癌患者中可行,特发性肺纤维化对微波消融治疗的I期非小细胞肺癌生存有不良影响。

研究设计与样本

  • 回顾性单中心队列研究,纳入2016年11月至2021年10月接受CT引导微波消融的临床I期非小细胞肺癌患者107例(特发性肺纤维化组27例,非特发性肺纤维化组80例),主要终点为90天不良事件和住院时间,次要终点为总生存期和无进展生存期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the safety and efficacy of microwave ablation (MWA) for stage I non-small cell lung cancer (NSCLC) in patients with idiopathic pulmonary fibrosis (IPF).

MATERIALS AND METHODS: A retrospective single-center cohort study was conducted in patients with clinical stage I NSCLC who underwent CT-guided MWA from Nov 2016 to Oct 2021. The patients were divided into the IPF group and the non-IPF group. The primary endpoints were 90-day adverse events and hospital length of stay (HLOS). The secondary endpoints included overall survival (OS) and progression-free survival (PFS).

RESULTS: A total of 107 patients (27 with IPF and 80 without IPF) were finally included for analysis. No procedure-related acute exacerbation of IPF or death occurred post-MWA. The rates of adverse events were similar between the groups (48.6% vs. 47.7%; p = 0.998). The incidence of grade 3 adverse events in the IPF group was higher than that in the non-IPF group without a significant difference (13.5% vs. 4.6%; p = 0.123). Median HLOS was 5 days in both groups without a significant difference (p = 0.078). The 1-year and 3-year OS were 85.2%/51.6% in the IPF group, and 97.5%/86.4% in the non-IPF group. The survival of patients with IPF was significantly poorer than the survival of patients without IPF (p < 0.001). There was no significant difference for PFS (p = 0.271).

CONCLUSION: MWA was feasible in the treatment of stage I NSCLC in patients with IPF. IPF had an adverse effect on the survival of stage I NSCLC treated with MWA.

CLINICAL RELEVANCE STATEMENT: CT-guided microwave ablation is a well-tolerated and effective potential alternative treatment for stage I non-small cell lung cancer in patients with idiopathic pulmonary fibrosis.

KEY POINTS: • Microwave ablation for stage I non-small cell lung cancer was well-tolerated without procedure-related acute exacerbation of idiopathic pulmonary fibrosis and death in patients with idiopathic pulmonary fibrosis. • No differences were observed in the incidence of adverse events between patients with idiopathic pulmonary fibrosis and those without idiopathic pulmonary fibrosis after microwave ablation (48.6% vs. 47.7%; p = 0.998). • The 1-year and 3-year overall survival rates (85.2%/51.6%) in the idiopathic pulmonary fibrosis group were worse than those in the non- idiopathic pulmonary fibrosis group (97.5%/86.4%) (p < 0.001).

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Peng J, Bie Z, Li Y, et al. Safety and efficacy of CT-guided percutaneous microwave ablation for stage I non-small cell lung cancer in patients with comorbid idiopathic pulmonary fibrosis. Eur Radiol. 2023. PMID: 38114848. doi:10.1007/s00330-023-10510-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。